Moderna stock was rising early on Monday after the Food and Drug Administration gave limited approval to the company’s newest Covid-19 vaccine.

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option.

The Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for specific high-risk populations, the company announced Saturday. This marks a ...

The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it. It's not a replacement for the company’s existing shot, but a second option.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food and Drug Administration.

Moderna Inc. gained US approval for a new Covid vaccine for a narrower group of people, in the latest sign that regulators are restricting access to immunizations under the leadership of Health ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing Covid shot does not currently face.

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to 64 years at high risk for severe disease, aligning with the agency ...